Neurotech clinches key milestone: first shipment of improved autism devices
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Neurotech International (ASX:NTI) has completed the first shipments of an improved version of its neurofeedback device, Mente Autism.
Pre-orders had been received from several of NTI’s distributors, and the devices are being delivered to Australia, Europe and the Middle East. Several distribution partners in these regions have begun marketing and information campaigns that will coincide with the release of the next batch of devices.
NTI is also preparing new marketing assets that can be used by distributors to promote Mente Autism in the local press and with key opinion leaders.
Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder (ASD). Designed for home use, it helps relax the minds of children on the spectrum, which in turn helps them to focus and engage positively with their environment.
The recently announced promising US clinical trial results provide NTI with important scientific evidence supporting the use of Mente Autism for children with ASD. As well as carrying significant weight with new and existing distributors of the device, the trial provides pivotal evidence to accompany the FDA submission for Mente Autism.
On top of this, NTI also expects to complete several multi-site studies that will further validate the product in different target markets. These studies are aimed at generating awareness and acceptance of the technology, in addition to supporting potential reimbursement.
To this end, NTI has recently appointed a consultant, Mediclever, to support applications for inclusion of Mente Autism on government reimbursement schemes in Australia. The costs of these projects will largely be borne by research institutions and their associated grant funding, with NTI donating research units and analytical support towards the studies.
As part of this process, NTI will also ship 20 research devices to academic partners in Italy and the Middle East, who have agreed to conduct studies in their respective regions, kicking off in September. Additional research agreements are currently being finalised.
As always, it should be noted that NTI is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
Neurotech CEO, Wolfgang Storf, commented: “We are pleased to commence shipping of the improved Mente Autism device to our distribution partners across Europe, Middle East and Australia. This is an important milestone following the US Clinical Trial and we look forward to fulfilling additional orders from our partners. We are ramping up production with a view to completing another shipment of devices in the coming weeks.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.